Publications

Some publications of Lipid Meta­bol­ism Study Group from recent years

Taskinen MR, Björnson E, Matikainen N, Söderlund S, Pietiläinen K, Ainola M, Hakkarainen A, Lundbom N, Fuchs J, Thorsell A, Adiels M, Andersson L, Packard C, Boren J. Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes. Diabetes Obes Metab. 2021

Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard C, Boren J. Effects of evolocumab on the postprandial kinetics of apolipoprotein B100 and B48-containing lipoproteins in type 2 diabetic subjects. ATVB 2020

Borén J, Packard CJ, Taskinen MR. The roles of apoC-III on the metabolism of triglyceride-rich lipoproteins in human. Front Endocrinol 11:474, 2020

Taskinen MR, Elias Björnson E, Andersson L, Kahri J, Porthan K, Matikainen N, Söderlund S, Pietiläinen K, Hakkarainen A, Lundbom N, Nilsson R, Ståhlman M, Adiels M, Parini P, Packard C and Borén J. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceriderich lipoproteins in type 2 diabetic subjects. J Clin Lipidol.14(1):77-87, 2020

Björnson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Söderlund S, Kahri J, Hakkarainen A, Lundbom N, Lundbom J, Sihlbom C, Thorsell A, Zhou H, Taskinen MR, Borén J. Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects. J Intern Med. 288(4):422-438, 2020

Packard CJ, Borén J, Taskinen MR. Causes and consequences of hypertriglyceridemia. Front Endocrinol 11:252, 2020

Boren J, Adiels M, Björnson E, Matikainen N, Söderlund S, Rämö J, Ripatti P, Ripatti S, Palotie A, Mancina RM, Hakkarainen A, Romeo S, Packard, CJ, Taskinen MR.   Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight 5(24):144079, 2020

Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard C, Boren J. Effects of evolocumab on the postprandial kinetics of apolipoprotein B100 and B48-containing lipoproteins in type 2 diabetic subjects. ATVB 2020

Björnson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Söderlund S, Kahri J, Taskinen MR and Borén J. Investigation of human apoB48 metabolism in chylomicron and VLDL subfractions using a new, integrated non-steady-state model of apoB48- and apoB100 kinetics. JIM 285(5):562-577, 2019

Matikainen N, Söderlund S, Björnson E, Pietiläinen K, Hakkarainen A, Lundbom N, Taskinen MR and Borén J. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk-factors in humans with adequately controlled type 2 diabetes: A single-centre randomised controlled study. Diabetes Obes Metab, 21(1):84-94 2019

Taskinen MR, Packard CJ and Borén J. Dietary fructose and the Metabolic Syndrome. Nutrients 11(9):1987, 2019

RSS Feed

No results.